Imugene Appoints Bachem to Manufacture Peptide in Imugene’s HER-2+ Cancer Vaccine

Melbourne, 27 May 2014: Australian immuno-oncology company Imugene Limited (ASX:IMU) has appointed Bachem AG to undertake clinical-grade manufacture of the peptide component of its proprietary therapeutic HER-2+ cancer vaccine HER-Vaxx.

Bachem has extensive experience in synthesising clinical grade peptides suitable for incorporation and assembly into the vaccine delivery platform to be used in HER-Vaxx, and has previously manufactured the peptides (three individual peptide B-cell epitope antigens) used in the completed Phase 1 breast cancer trial. All three peptides are being combined into a single (longer) version of peptide, which could potentially result in manufacturing challenges.

Bachem has now completed a successful feasibility for this longer peptide, and hence manufacture of the vaccine has now commenced.

HER-Vaxx is a proprietary therapeutic cancer vaccine that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the US$6.9 billion per annum drug Herceptin®. HER-Vaxx has successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 2 study in gastric cancer.

Dr Nick Ede, Executive Director Imugene said, "Over my 25 years in the global peptide community from both the scientific and business perspective, Bachem has been a constant in quality and experience. Given Bachem’s experience in supplying peptides in the form suitable for our vaccine delivery platform, this is a logical choice for the manufacture our clinical grade peptide."

-ends

Contact :
Paul A Hopper
Executive Chairman
+1 858 334 5820 (US)
+61 406 671 515 (Australia)
receptogen[at]earthlink.net

Dr Nick Ede
Executive Director
+61 400 642 254
nede[at]imugene.com

Media contact: Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology focused biopharmaceutical company developing HER2 +ve gastric and breast cancer vaccines. The Company’s lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER-2/neu.
HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com